- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform | 1 | Benzinga.com | ||
| Mo | HCW Biologics meldet vielversprechende Ergebnisse für neue Krebs-Immuntherapie | 13 | Investing.com Deutsch | ||
| Mo | HCW Biologics stock soars on novel cancer immunotherapy breakthrough | 1 | Investing.com | ||
| Mo | HCW Biologics reports promising results for new cancer immunotherapy | 1 | Investing.com | ||
| Mo | HCW Biologics Inc.: HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market | 3 | GlobeNewswire (USA) | ||
| 19.08. | HCW Biologics erhält Delisting-Mitteilung von der NASDAQ und plant Anhörung | 3 | Investing.com Deutsch | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 19.08. | HCW Biologics GAAP EPS of -$16.16, revenue of $180.4M | 1 | Seeking Alpha | ||
| 19.08. | HCW Biologics GAAP EPS of -$16.16 | 1 | Seeking Alpha | ||
| 18.08. | HCW Biologics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 18.08. | HCW Biologics Inc.: HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results | 715 | GlobeNewswire (Europe) | MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 15.08. | HCW Biologics Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 14.08. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.07. | HCW Biologics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.07. | HCW Biologics meldet vollständige Ausübung von vorfinanzierten Optionsscheinen durch Armistice Capital | 7 | Investing.com Deutsch | ||
| 01.07. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.06. | HCW Biologics entwickelt neue T-Zell-Engager für Bauchspeicheldrüsenkrebs | 1 | Investing.com Deutsch | ||
| 27.06. | HCW Biologics develops new T-cell engagers for pancreatic cancer | 1 | Investing.com | ||
| 27.06. | HCW Biologics Inc.: HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors | 1 | GlobeNewswire (USA) | ||
| 26.06. | HCW Biologics regains compliance with Nasdaq Capital Market requirements | 1 | Seeking Alpha | ||
| 26.06. | HCW Biologics erfüllt wieder alle Nasdaq-Notierungsanforderungen | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| BIOXXMED | 0,420 | 0,00 % | EQS-Adhoc: bioXXmed AG: Verbindliches Angebot für die Tochtergesellschaft Rancoderm GmbH aus dem M&A-Prozess angenommen; Kapitalmaßnahme zur Sicherstellung der Liquidität beabsichtigt | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Verkauf
bioXXmed AG: Verbindliches Angebot für die Tochtergesellschaft Rancoderm GmbH aus dem M&A-Prozess angenommen; Kapitalmaßnahme zur Sicherstellung... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| OCUGEN | 0,860 | -0,53 % | Ocugen - Novel cell therapies for retinal diseases | Ocugen's modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,920 | -2,13 % | EQS-DD: Bio-Gate AG: Karl Richter, Zeichnung von Wandelschuldverschreibungen | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
21.08.2025 / 17:58... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,504 | +3,28 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Debenture Units Financing | Montreal, Quebec--(Newsfile Corp. - August 22, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specialized in drug... ► Artikel lesen | |
| VAXART | 0,272 | 0,00 % | Vaxart, Inc.: Vaxart Granted Extension by Nasdaq to Regain Compliance | - Company must regain compliance with the Nasdaq Bid Price Rule on or before the October 17, 2025 deadline - SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT)... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,550 | -4,91 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 First Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - August 13, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 4,870 | +3,84 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| IMMUNIC | 0,700 | +0,14 % | IMMUNIC, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| AIM IMMUNOTECH | 0,073 | 0,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| CEL-SCI | 10,580 | +13,70 % | CEL SCI CORP - S-8, Securities to be offered to employees in employee benefit plans |
Das Unternehmen HCW BIOLOGICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,060 (+1,06 %) liegt der Kurs bei 5,740 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.